- Conditions
- Growth Hormone Deficiency
- Interventions
- No intervention
- Other
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
- Interventions
- Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
- Combination Product
- Lead sponsor
- Ascendis Pharma A/S
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 19
- States / cities
- Palo Alto, California • Sacramento, California • Aurora, Colorado + 15 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- No intervention
- Drug
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
- Conditions
- Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Interventions
- Lonapegsomatropin, Placebo, Somatropin
- Drug · Other
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 23 Years to 80 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
- Conditions
- Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Interventions
- Lonapegsomatropin
- Drug
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 23 Years to 81 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Torrance, California • Chicago, Illinois + 12 more
- Conditions
- Turner Syndrome
- Interventions
- Lonapegsomatropin, Somatropin
- Biological · Drug
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 1 Year to 10 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 19
- States / cities
- Palo Alto, California • San Diego, California • Aurora, Colorado + 16 more